Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonidegib - Sun Pharmaceutical Industries

Drug Profile

Sonidegib - Sun Pharmaceutical Industries

Alternative Names: Erismodegib; Erismodegib-phosphate; LDE-225; NVP-LDE-225; Odomzo; Sonidegib-phosphate

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Academic Medical Center; Celgene Corporation; Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Sanofi; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; Sun Pharmaceutical Industries; University of Alabama at Birmingham; University of Zurich
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Pancreatic cancer
  • No development reported Breast cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Liver cancer; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 20 Oct 2023 Efficacy data from a phase II BOLT trial in Basal cell carcinoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 13 Aug 2021 Novartis Pharmaceuticals in collaboration with Mayo Clinic completed a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT02086552)
  • 04 Jun 2021 Efficacy and adverse events data from a phase II trial in Pancreatic cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top